

The role of milk protein and other dried milk products in the growth and development of stunted children

Submission date 06/01/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 13/01/2020	Overall study status Completed	<input checked="" type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 02/02/2026	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Stunting affects one of every four children globally, and is associated with delayed physical and cognitive development, and reduced working capacity and educational achievement. Childhood stunting therefore impairs human capital, and it may also increase the risk of chronic diseases later in life. Milk has been shown to play a role in growth, but it is not clear if such effects are due to the protein or to lactose and minerals (in whey permeate) in milk.

This study aims to assess the effects of milk protein and whey permeate in a lipid-based nutrient supplement (LNS) on growth in children with stunting.

Who can participate?

Children aged 12 – 59 months with stunted growth.

What does the study involve?

Participants will be randomly allocated to one of five groups. Groups 1 – 4 will receive a different LNS for 12-weeks, group 5 will not receive any supplement. Participants will be measured to assess growth over the 12 weeks as well as priding blood and stool samples.

What are the possible benefits and risks of participating?

It is expected that all children will benefit from the experimental products and/or the nutrition counselling, as well as the medical assessments and referrals, if needed. Apart from low risk of allergic reactions to milk or peanut, the products are not likely to pose any risks.

Where is the study run from?

1. Buwenge Health Centre IV, Uganda
2. Walukuba Health Centre IV, Uganda

When is the study starting and how long is it expected to run for?

January 2020 to December 2020 (updated 11/11/2020, previously: January 2021) (updated 14/07/2020, previously: September 2020)

Who is funding the study?

1. ARLA Food for Health, Denmark
2. Danish Dairy Research Foundation, Denmark
3. Nutriset, France
4. University of Copenhagen, Denmark

Who is the main contact?

Prof Henrik Friis

hfr@nexs.ku.dk

Dr Ezekiel Mupere

mupez@yahoo.com

Contact information

Type(s)

Scientific

Contact name

Prof Henrik Friis

ORCID ID

<https://orcid.org/0000-0002-2848-2940>

Contact details

Rolighedsvej 26

Frederiksberg

Denmark

1958

+45 26253968

hfr@nexs.ku.dk

Type(s)

Scientific

Contact name

Dr Ezekiel Mupere

ORCID ID

<https://orcid.org/0000-0002-8746-9009>

Contact details

Paediatrics and Child Health

Makerere University

Kampala

Uganda

P.O Box 7072

+256 776 161 327

mupez@yahoo.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

D222

Study information

Scientific Title

The role of milk protein and whey permeate in the growth and development of stunted children: a randomised controlled trial in Eastern Uganda

Acronym

MAGNUS

Study objectives

1. Milk protein and whey permeate in a lipid-based nutrient supplement (LNS) increases linear growth among children with stunting
2. Milk protein and whey permeate in a LNS increases ponderal growth and fat-free mass accretion, haemoglobin, and child development among children with stunting
3. Supplementation with LNS, with or without milk ingredients, increases linear and ponderal growth, fat-free mass accretion, haemoglobin and child development in children with stunting
4. The effects of milk protein and whey permeate in LNS, or LNS itself, on linear and ponderal growth, fat-free mass accretion, haemoglobin and child development in children with stunting, are mediated by effects on markers of environmental enteric dysfunction

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/12/2019, School of Medicine Research and Ethics committee (SOMREC) at Makerere University (PO Box 7072, Kampala, Uganda; +256 414 533541; rresearch9@gmail.com), ref: 2019-013

Study design

Randomized controlled double-blind two-by-two factorial trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Stunting

Interventions

Children in four study arms will receive a lipid-based nutrient supplement (LNS, 100 gram containing 530 kcal per day) with or without whey permeate and milk protein isolate using a 2-by-2 factorial design. The supplements contain similar proportions of energy, protein and carbohydrates. Each formulation contains a mineral and vitamin mix. The minerals provided by the whey permeate are in addition. The supplements have similar appearance, texture, colour and taste. Children in a fifth study arm will not be supplemented, and serve as a reference. Children in all study arms will receive nutrition counselling. The duration of the intervention is 12 weeks.

Groups:

1. LNS with whey permeate and milk protein isolate
2. LNS with whey permeate and without milk protein isolate
3. LNS without whey permeate and with milk protein isolate
4. LNS without whey permeate and without milk protein isolate
5. No supplement

In 2 and 4, milk protein isolate is replaced by soy protein isolate. In 3 and 4, whey permeate is replaced by maltodextrin.

Randomisation will be done stratified by site and using variable block size.

Intervention Type

Supplement

Primary outcome(s)

Measured at baseline and 12-weeks:

1. Knee-heel length (mm)
2. Height (cm)

Key secondary outcome(s)

Measured at baseline and 12-weeks:

1. Mid-upper arm circumference (mm)
 2. Weight (g)
 3. Height-for-age z-scores (HAZ)
 4. Weight-for-height z-scores (WHZ)
 5. Weight-for-age z-scores (WAZ)
 6. Child development index (CDI)
 7. Head circumference (cm)
 8. Bioimpedance: Fat mass (FM, kg), fat-free mass (FFM, kg), fat mass index (FMI, kg/m²), fat-free mass index (FFMI, kg/m²)
 9. Skin folds: triceps, subscapularis (mm)
- Blood tests:
10. Haemoglobin (g/L)
 11. Serum/plasma insulin-like Growth Factor-1 (IGF-1)
 12. Serum/plasma insulin
 13. Serum C-reactive protein
 14. Serum alpha-1-acid glycoprotein
 15. Plasma citrulline
 16. Serum ferritin and transferrin receptors (markers of iron status)
 17. Plasma cobalamin and methylmalonic acid (markers of B12 status)
 18. Plasma folate

19. Serum retinol

Fecal tests:

20. Fecal myeloperoxidase

21. Fecal neopterin

22. Fecal alpha-1-antitrypsin

23. Gut microbiota

24. Morbidity (including diarrhea, pneumonia, fever, malaria), safety (deterioration to MAM or SAM and mortality) measured using patient records

Completion date

18/12/2020

Eligibility

Key inclusion criteria

1. Age 12 - 59 months

2. Height-age-Z < -2 according to WHO growth standards (2006)

3. Care-taker able and willing to return for follow-up visits and agrees to phone follow-up

4. Living within the catchment area

5. Written informed consent given by parent/caregiver

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Child

Lower age limit

12 months

Upper age limit

59 months

Sex

All

Total final enrolment

750

Key exclusion criteria

1. Severe acute malnutrition, defined as MUAC <115 mm OR WHZ<-3 OR bilateral pitting oedema

2. Medical complications requiring hospitalization

3. Obvious disability that impedes eating capacity

4. Disability that makes length/height assessment problematic

5. Participation in another study which impacts on this study or previous enrollment in this study
6. Family plans to move away from the catchment area in the next 6 months
7. History or known allergy to peanuts or milk

Date of first enrolment

31/01/2020

Date of final enrolment

30/06/2020

Locations

Countries of recruitment

Uganda

Study participating centre

Buwenge Health Centre IV

Jinja

Uganda

TBD

Study participating centre

Walukuba Health Centre IV

Jinja

Uganda

TBD

Sponsor information

Organisation

University of Copenhagen

ROR

<https://ror.org/035b05819>

Funder(s)

Funder type

Research organisation

Funder Name
ARLA Food for Health, Denmark

Funder Name
Danish Dairy Research Foundation, Denmark

Funder Name
Nutrisset, France

Funder Name
University of Copenhagen, Denmark

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Analysis of plasma citrulline levels and correlations	23/05/2023	24/05/2023	Yes	No
Results article		20/12/2023	27/12/2023	Yes	No
Results article		06/06/2023	02/02/2026	Yes	No
Protocol article		24/04/2021	13/08/2021	Yes	No
Other publications	Secondary analysis	24/01/2024	29/01/2024	Yes	No
Other publications	Correlates of body composition	05/08/2024	09/08/2024	Yes	No
Other publications	Correlates of early child development	30/01/2024	02/02/2026	Yes	No
Other publications	Correlates of iron, cobalamin, folate, and vitamin A status		02/02/2026	Yes	No
Other publications	Micronutrient status and other correlates of hemoglobin	29/08/2023	02/02/2026	Yes	No
Other publications	Secondary analysis	03/03/2025	02/02/2026	Yes	No

Other publications	Secondary analysis	31/03 /2025	02/02 /2026	Yes	No
Other publications	Secondary analysis	15/08 /2024	02/02 /2026	Yes	No
Protocol file	version V5	03/12 /2019	11/11 /2020	No	No
Statistical Analysis Plan	version 01	16/04 /2021	19/04 /2021	No	No